<DOC>
	<DOCNO>NCT01894256</DOCNO>
	<brief_summary>This 2-part study patient advance solid tumour . Part A investigate PK olaparib patient mild moderate renal impairment compare patient normal renal function ; Part B allow eligible study patient continue access olaparib PK phase provide additional safety data .</brief_summary>
	<brief_title>Study Assess Blood Levels Safety Olaparib Patients With Advanced Solid Tumours Normal Impaired Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Olaparib</mesh_term>
	<criteria>Inclusion criterion : For inclusion study patient renal impairment , follow criterion must meet : 1 . Patients must stable renal impairment ( moderate mild ) , depend creatinine clearance estimate use CockcroftGault equation ( moderate 31 50 mL/min ; mild 51 80 mL/min ) , least 2 month prior start study . For inclusion study patient normal renal function , follow criterion must meet : 2 . Calculated serum creatinine clearance great equal 81 mL/min ( use CockcroftGault equation ) . All patient must fulfil follow criterion : 3 . Provision write informed consent prior study specific procedure . 4 . Patients must great equal 18 less equal 75 year age . 5 . Histologically , appropriate , cytologically confirm malignant solid tumour refractory resistant standard therapy suitable effective standard therapy exist . 6 . BMI 1830 kg/m2 . 7 . Normal liver bone marrow function measure within 28 day prior administration IP define : Haemoglobin ( Hb ) great equal 10.0 g/dL , blood transfusion previous 28 day . Absolute neutrophil count ( ANC ) great equal 1.5 x 109/L . White blood cell ( WBC ) great 3 x 109/L . Platelet count great equal 100 x 109/L . Total bilirubin less equal 1.5 x institutional upper limit normal ( ULN ) ( except case Gilbert 's disease ) . Aspartate aminotransferase serum glutamic oxaloacetic transaminase ( AST ) , alanine aminotransferase serum glutamic pyruvic transaminase ( ALT ) less equal 2.5 x institutional ULN unless liver metastasis present case must less equal 5x ULN . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . 9 . Patients must life expectancy great equal 12 week . 10 . Evidence non childbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment Day 1 first treatment period Part A. Postmenopausal define : Amenorrheic 1 year follow cessation exogenous hormonal treatment . Luteinising hormone folliclestimulating hormone level postmenopausal range woman 50 year age . Radiationinduced oophorectomy last menses great 1 year ago . Chemotherapyinduced menopause great 1 year interval since last menses Surgical sterilisation ( bilateral oophorectomy hysterectomy ) . 11 . Patients willing able comply protocol duration study include undergoing treatment schedule visit examination . 12 . Patients must stable concomitant medication regimen ( exception electrolyte supplement ) , define change medication dose within 2 week prior start olaparib dose , except bisphosphonates , denosumab corticosteroid , stable least 4 week prior start olaparib dosing . Exclusion criterion : Patients must enter study follow exclusion criterion fulfil : 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff , agent and/or staff study site ) . 2 . Previous enrolment present study . 3 . Participation another clinical study investigational medicinal product ( IP ) last 14 day ( long period depend defined characteristic agent use ) . 4 . Renal transplant end stage renal disease ( ESRD ) patient . 5 . Patients receive systemic chemotherapy radiotherapy ( except palliative reason ) within 2 week prior study treatment ( long period depend defined characteristic agent use ) . The patient receive stable dose bisphosphonates denosumab bone metastasis study long start least 4 week prior treatment . 6 . Patients receive receive inhibitor inducer CYP3A4 within washout period . 7 . For Part A , drug affect creatinine clearance cephalosporin antibiotic , ascorbic acid , trimethoprim , cimetidine quinine use within 7 day prior dose olaparib . 8 . Treatment previous 3 month drug know welldefined potential hepatotoxicity ( eg , halothane ) . 9 . Persistent toxicity ( great equal CTCAE Grade 2 ) cause previous cancer therapy , exclude alopecia . 10 . Patients myelodysplastic syndrome/acute myeloid leukaemia . 11 . Patients symptomatic uncontrolled brain metastasis . A scan confirm absence brain metastasis require . Patients asymptomatic brain metastasis symptomatic stable brain metastasis receive stable dose corticosteroid study long start least 4 week prior treatment . 12 . Major surgery within 2 week start study treatment patient must recover effect major surgery . 13 . Patients consider poor medical risk due serious uncontrolled medical disorder , non malignant systemic disease , uncontrolled seizure , active uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , uncontrolled major seizure disorder , unstable spinal cord compression , superior vena cava syndrome , extensive bilateral interstitial lung disease high resolution computer tomography ( HRCT ) scan , psychiatric disorder prohibits obtain informed consent . 14 . Patients history heart failure leave ventricular dysfunction . 15 . Patients gastric , gastrooesophageal oesophageal cancer . 16 . Patients unable swallow orally administer medication patient gastrointestinal disorder significant gastrointestinal resection likely interfere absorption olaparib . 17 . Breastfeeding woman . 18 . Immunocompromised patient eg , patient know serologically positive human immunodeficiency virus ( HIV ) . 19 . Patients know active hepatic disease ( eg , hepatitis B C ) . 20 . Patients know hypersensitivity olaparib excipients product . 21 . Resting ECG screen measurable QTc great 470 msec 2 time point within 24 hour period family history long QT syndrome . 22 . Clinical judgment investigator patient participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>oncology ,</keyword>
	<keyword>cancer ,</keyword>
	<keyword>neoplasm ,</keyword>
	<keyword>anticancer drug ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>area curve ,</keyword>
	<keyword>olaparib ,</keyword>
	<keyword>solid tumour ,</keyword>
	<keyword>mild renal impairment ,</keyword>
	<keyword>moderate renal impairment</keyword>
</DOC>